Robert L. Rosiello has been appointed executive vice president, Valeant Pharmaceuticals, and will take over the role of chief financial officer effective July 1. He succeeds Howard Schiller as CFO, who will remain on Valeant’s Board and serve as a consultant.   Mr. Rosiello spent 30 years with McKinsey & Company working with healthcare, technology and consumer companies to deliver growth through M&A and financial performance improvement. As Senior Partner in charge of the global me...